Nuveen’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $47.6M | Sell |
583,829
-83,190
| -12% | -$6.01M | 0.01% | 734 |
|
|
2026
Q1 | $45.4M | Sell |
667,019
-32,171
| -5% | -$2.28M | 0.01% | 700 |
|
|
2025
Q4 | $53.1M | Sell |
699,190
-22,012
| -3% | -$1.6M | 0.01% | 611 |
|
|
2025
Q3 | $44.3M | Sell |
721,202
-247,690
| -26% | -$12.9M | 0.01% | 683 |
|
|
2025
Q2 | $47.3M | Sell |
968,892
-40,276
| -4% | -$1.91M | 0.01% | 634 |
|
|
2025
Q1 | $51.4M | Sell |
1,009,168
-68,626
| -6% | -$3.42M | 0.02% | 615 |
|
|
2024
Q4 | $48.7M | Buy |
1,077,794
+273,638
| +34% | +$11.7M | 0.01% | 660 |
|
|
2024
Q3 | $29.8M | Buy |
804,156
+117,631
| +17% | +$3.94M | 0.01% | 930 |
|
|
2024
Q2 | $21M | Buy |
686,525
+219,865
| +47% | +$7.12M | 0.01% | 1100 |
|
|
2024
Q1 | $13.6M | Buy |
466,660
+174,259
| +60% | +$4.88M | ﹤0.01% | 1411 |
|
|
2023
Q4 | $8.06M | Buy |
292,401
+82,897
| +40% | +$1.9M | ﹤0.01% | 1727 |
|
|
2023
Q3 | $4.69M | Sell |
209,504
-1,780
| -0.8% | -$66.2K | ﹤0.01% | 1896 |
|
|
2023
Q2 | $8.59M | Buy |
211,284
+2,032
| +1% | +$99.4K | ﹤0.01% | 1606 |
|
|
2023
Q1 | $10.1M | Buy |
209,252
+14,091
| +7% | +$644K | ﹤0.01% | 1475 |
|
|
2022
Q4 | $7.45M | Sell |
195,161
-16,209
| -8% | -$674K | ﹤0.01% | 1681 |
|
|
2022
Q3 | $10.6M | Sell |
211,370
-2,662
| -1% | -$130K | ﹤0.01% | 1438 |
|
|
2022
Q2 | $8.57M | Sell |
214,032
-64,891
| -23% | -$2.28M | ﹤0.01% | 1614 |
|
|
2022
Q1 | $5.79M | Buy |
278,923
+71,502
| +34% | +$2.75M | ﹤0.01% | 1980 |
|
|
2021
Q4 | $4.3M | Sell |
207,421
-35,905
| -15% | -$1.37M | ﹤0.01% | 2211 |
|
|
2021
Q3 | $5.05M | Sell |
243,326
-9,153
| -4% | -$376K | ﹤0.01% | 2206 |
|
|
2021
Q2 | $5.24M | Buy |
252,479
+1,585
| +0.6% | +$67.9K | ﹤0.01% | 2220 |
|
|
2021
Q1 | $5.21M | Sell |
250,894
-7,221
| -3% | -$429K | ﹤0.01% | 2150 |
|
|
2020
Q4 | $5.36M | Sell |
258,115
-2,914
| -1% | -$172K | ﹤0.01% | 2037 |
|
|
2020
Q3 | $5.42M | Sell |
261,029
-26,837
| -9% | -$1.32M | ﹤0.01% | 1871 |
|
|
2020
Q2 | $5.97M | Sell |
287,866
-254,368
| -47% | -$12.5M | ﹤0.01% | 1802 |
|
|
2020
Q1 | $24.2M | Sell |
542,234
-117,857
| -18% | -$5.93M | 0.01% | 801 |
|
|
2019
Q4 | $31.7M | Buy |
660,091
+365,512
| +124% | +$15.5M | 0.01% | 916 |
|
|
2019
Q3 | $9.96M | Buy |
294,579
+15,434
| +6% | +$672K | ﹤0.01% | 1577 |
|
|
2019
Q2 | $12.6M | Buy |
+279,145
| New | +$11M | ﹤0.01% | 1458 |
|
|
2015
Q4 | – | Sell |
-18,166
| Closed | -$485K | – | 1566 |
|
|
2015
Q3 | $485K | Buy |
+18,166
| New | +$777K | ﹤0.01% | 1333 |
|
|
2014
Q3 | – | Sell |
-8,758
| Closed | -$317K | – | 1627 |
|
|
2014
Q2 | $317K | Buy |
+8,758
| New | +$187K | ﹤0.01% | 1449 |
|
Other funds holding PTCT
RI
JT
Nuveen's PTCT Position: Q2 2026 in Review
Nuveen reduced its PTC Therapeutics (PTCT) stake by 12% in Q2 2026, selling an estimated $6.01M and leaving 583,829 shares worth $47.6M. The position accounts for 0.01% of the portfolio, ranked #734.
Nuveen first reported a position in PTCT in Q2 2014 and has held it in 31 quarters since. The position peaked at $53.1M in Q4 2025. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.
- Nuveen held 583,829 shares of PTC Therapeutics worth $47.6M as of Q2 2026.
- Nuveen sold 83,190 PTC Therapeutics shares in Q2 2026, an estimated $6.01M.
- PTC Therapeutics made up 0.01% of Nuveen's portfolio in Q2 2026, its #734 holding.
- Nuveen first reported a position in PTC Therapeutics in Q2 2014 and has held it in 31 quarters since.
- Nuveen's PTC Therapeutics position peaked at $53.1M in Q4 2025.
- 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.
Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.